Unknown PHASE1 INTERVENTIONAL 7-arm NCT05655221

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

A First-in-human, Randomized, Double-blind, Parallel, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Sponsor: Tasly Biopharmaceuticals Co., Ltd.

Conditions Nonalcoholic Steatohepatitis

Interventions B1344 Placebo

Updated 4 times since 2023 Last updated: Dec 8, 2022 Started: Aug 30, 2022 Primary completion: Jul 31, 2023 Completion: Jan 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05655221, this PHASE1 trial focuses on Nonalcoholic Steatohepatitis and remains ongoing. Sponsored by Tasly Biopharmaceuticals Co., Ltd., it has been updated 4 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jan 2023 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tasly Biopharmaceuticals Co., Ltd.

Data source: Tasly Biopharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Glendale, United States